Suppr超能文献

暴发性巨细胞心肌炎的致命复发及在启动替代免疫抑制方案后的恢复

Fatal recurrence of fulminant giant cell myocarditis and recovery after initialisation of an alternative immunosuppressive regime.

作者信息

Fluschnik Nina, Escher Felicitas, Blankenberg Stefan, Westermann Dirk

机构信息

Department of General and Interventional Cardiology, University Heart Center, Hamburg Eppendorf, Hamburg, Germany.

Department of Cardiology and Pneumology, Charité Berlin, Campus Benjamin Franklin (CBF), Berlin, Germany.

出版信息

BMJ Case Rep. 2014 Sep 22;2014:bcr2014206386. doi: 10.1136/bcr-2014-206386.

Abstract

We report on a challenging case of a 34-year-old male patient with giant cell myocarditis (GCM) and fulminant relapse after discontinuing immunomodulatory therapy 2 years after the initial event. Specific combined immunosuppressive therapy with antithymocyte globulin (ATG), cyclosporine and high-dose glucocorticoids combined with guideline-based heart failure medication led to the recovery of GCM, improvement of systolic left ventricular function and clinical remission. This case report emphasises the importance of an immunosuppressive therapy for the prognosis and outcome and the risk of discontinuation. Most importantly, ATG seems to be one new possible potential treatment option for patients with acute GCM.

摘要

我们报告了一例具有挑战性的病例,一名34岁男性患者患有巨细胞性心肌炎(GCM),在初次发病2年后停用免疫调节治疗后出现暴发性复发。使用抗胸腺细胞球蛋白(ATG)、环孢素和高剂量糖皮质激素进行特异性联合免疫抑制治疗,并结合基于指南的心力衰竭药物治疗,使GCM得以恢复,左心室收缩功能得到改善,临床症状缓解。本病例报告强调了免疫抑制治疗对预后和结局的重要性以及停药风险。最重要的是,ATG似乎是急性GCM患者一种新的潜在治疗选择。

相似文献

2
Combined immunosuppression for the treatment of idiopathic giant cell myocarditis.
Mayo Clin Proc. 1999 Dec;74(12):1221-6. doi: 10.4065/74.12.1221.
3
Usefulness of immunosuppression for giant cell myocarditis.
Am J Cardiol. 2008 Dec 1;102(11):1535-9. doi: 10.1016/j.amjcard.2008.07.041. Epub 2008 Sep 18.
5
Relapse of giant cell myocarditis supported with veno-arterial extracorporeal membrane oxygenation.
Interact Cardiovasc Thorac Surg. 2011 May;12(5):829-31. doi: 10.1510/icvts.2010.250035. Epub 2011 Feb 5.
7
Heart Transplantation for Giant Cell Myocarditis: A Case Series.
Transplant Proc. 2021 Jan-Feb;53(1):348-352. doi: 10.1016/j.transproceed.2020.10.047. Epub 2020 Dec 29.
9
Giant cell myocarditis responding to immunosuppressive therapy.
Chest. 2000 Mar;117(3):905-7. doi: 10.1378/chest.117.3.905.
10
The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis.
J Card Fail. 2002 Apr;8(2):74-8. doi: 10.1054/jcaf.2002.32196.

本文引用的文献

1
An alternative immunosuppressive regimen to prolong transplant free survival in a patient with giant cell myocarditis.
Int J Cardiol. 2013 Sep 20;168(1):e27-8. doi: 10.1016/j.ijcard.2013.05.078. Epub 2013 Jun 2.
2
Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression.
Circ Heart Fail. 2013 Jan;6(1):15-22. doi: 10.1161/CIRCHEARTFAILURE.112.969261. Epub 2012 Nov 13.
3
Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis.
Eur J Heart Fail. 2012 Mar;14(3):312-8. doi: 10.1093/eurjhf/hfr174. Epub 2012 Jan 20.
4
Usefulness of immunosuppression for giant cell myocarditis.
Am J Cardiol. 2008 Dec 1;102(11):1535-9. doi: 10.1016/j.amjcard.2008.07.041. Epub 2008 Sep 18.
6
Combined immunosuppression for the treatment of idiopathic giant cell myocarditis.
Mayo Clin Proc. 1999 Dec;74(12):1221-6. doi: 10.4065/74.12.1221.
8
Heart transplantation for giant cell myocarditis.
J Heart Lung Transplant. 1994 May-Jun;13(3):555.
9
Giant Cell Myocarditis Study Group.
Am Heart J. 1995 Dec;130(6):1312. doi: 10.1016/0002-8703(95)90168-x.
10
Idiopathic giant cell myocarditis--a distinctive clinico-pathological entity.
Br Heart J. 1975 Feb;37(2):192-5. doi: 10.1136/hrt.37.2.192.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验